TScan Therapeutics Announces Upcoming Virtual Investor Event
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will host a virtual investor event on November 14, 2022, at 5:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will host a virtual investor event on November 14, 2022, at 5:00 PM ET. This event will review poster presentations from the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting related to their solid tumor TCR-T candidates. TScan's multiplexed therapy aims to address antigen heterogeneity and HLA loss in cancer treatment. Interested participants can register through the provided link, and a replay will be available on TScan’s website.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +0.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors
Monday, November 14th at 5:00 PM ET
WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will host a virtual investor event on Monday, November 14, 2022 at 5:00 p.m. ET.
The event will provide an in-depth review of the poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting related to solid tumor TCR-T candidates, as well as TScan’s approach to multiplexed therapy as a way to potentially overcome antigen heterogeneity and HLA loss.
To register for the event, please click here. A replay will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
Contact
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.